Ceftazidime/Avibactam Pfizer

Menu

Close

HomeAboutAbout Ceftazidime/avibactam PfizerPatient ProfilesIDSA guidelinesEfficacySafetyImportant Safety InformationSafety DataDosingMedical InformationVisit the Pfizer Medical Information Africa Website for Healthcare ProfessionalsSubmit a medical question to Pfizer

To report an adverse event, please contact [email protected]
Dosing Recommendations

Normal adult renal function

Adult renal impairment

Ceftazidime/Avibactam Pfizer (ceftazidime and avibactam) has consistent dosing across indications, with no dosage adjustments required in the elderly, adult patients with mild renal impairment (estimated CrCl > 50 to ≤80 mL/min) and those with hepatic impairment1Recommended dose for adult patients with estimated CrCl>50 mL/min1*
Adapted from Ceftazidime/Avibactam Pfizer [SmPC], Feb 2021.
*The dose of Ceftazidime/Avibactam Pfizer in adult patients with estimated CrCl ≤50 mL/min should be adjusted according to recommended doses. CrCl estimated using the Cockcroft-Gault formula.1
†To be used in combination with metronidazole when anaerobic pathogens are known or suspected to be contributing to the infectious process.1
‡To be used in combination with an antibacterial agent active against Gram-positive pathogens when these are known or suspected to be contributing to the infectious process.1
§The total duration shown may include intravenous Ceftazidime/Avibactam Pfizer followed by appropriate oral therapy.1
‖There is very limited experience with the use of Ceftazidime/Avibactam Pfizer for more than 14 days.1

​​​​​​​cIAI, complicated intra-abdominal infection; CrCl, creatinine clearance; cUTI, complicated urinary tract infection; HAP, hospital-acquired pneumonia;
VAP, ventilator-associated pneumonia.References:  1. Ceftazidime/Avibactam Pfizer [SmPC], Pfizer
Explore more Safety and tolerability Learn More Loading
Dosage adjustment is required for patients with renal impairment (estimated CrCl ≤50 mL/min)1Recommended dose adjustments in adult patients with estimated CrCl ≤50 mL/min:1
Adapted from Ceftazidime/Avibactam Pfizer [SmPC], Feb 2021.
*CrCl estimated using the Cockcroft–Gault formula.1
†Dose recommendations are based on PK modelling.1
‡Dosing of Ceftazidime/Avibactam Pfizer on haemodialysis days should occur after completion of haemodialysis.1

CrCl, creatinine clearance; ESRD, end-stage renal disease; PK, pharmacokinetic.Reference:
1. Ceftazidime/Avibactam Pfizer [SmPC], Pfizer
Explore more
Safety and tolerability Learn More Loading
Limited treatment options Learn MoreLoading
IDSA guidelines Learn MoreLoading

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

This site is intended only for Rwanda health care professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2022 Pfizer Inc. All rights reserved.

Disclaimer: The product is not yet licensed by the Board of Health of Rwanda (Rwanda FDA). The product has however obtained prior Board of Health approval for supply to Accord program channels in Rwanda.

You are now leaving Accord Portal to access Pfizer Medical Information Portal  You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.